A 72-year-old woman with hypertension and stage 3b CKD (eGFR 35 mL/min/1.73 m²) on losartan 50 mg daily presents with fatigue and muscle cramps for 1 week. She has no cardiac symptoms or palpitations. Physical examination is unremarkable. ECG shows normal sinus rhythm with no peaked T waves or QRS widening. Laboratory results: potassium 6.2 mEq/L, sodium 140 mEq/L, chloride 102 mEq/L, bicarbonate 24 mEq/L, creatinine 1.8 mg/dL. Urinalysis shows no proteinuria. What is the most appropriate next step in management?

Explanation

## Clinical Presentation & Risk Stratification This patient has **asymptomatic or mildly symptomatic hyperkalemia** (K⁺ = 6.2 mEq/L) **without ECG changes**. This is a **chronic or subacute hyperkalemia** scenario requiring **outpatient management**, not acute life-threatening intervention. **Key Point:** The **absence of peaked T waves, QRS widening, or cardiac symptoms** indicates the patient is NOT at imminent risk of ventricular fibrillation. Treatment should focus on **removing the cause and gradual K⁺ reduction**. ## Hyperkalemia Severity Classification | Severity | K⁺ Level | ECG Changes | Symptoms | Management | |----------|----------|-------------|----------|-------------| | **Mild** | 5.5–6.0 | None | None | Dietary restriction, monitor | | **Moderate** | 6.0–7.0 | None or peaked T | Mild (cramps, weakness) | Remove cause, cation exchanger, diuretics | | **Severe** | >7.0 | Peaked T, QRS widening, bradycardia | Palpitations, syncope risk | **Acute: Calcium + insulin/dextrose + bicarbonate** | This patient falls into the **moderate category** with no ECG changes — outpatient management is appropriate. ## Stepwise Management Algorithm ```mermaid flowchart TD A[K+ 6.2, no ECG changes, no symptoms]:::outcome --> B{Identify cause}:::decision B -->|ACE-I/ARB/K-sparing diuretic| C[Discontinue offending agent]:::action B -->|Dietary excess| D[Low-K diet counseling]:::action B -->|Renal disease| E[Monitor renal function]:::action C --> F[Start alternative antihypertensive]:::action F --> G[Amlodipine or hydralazine]:::action D --> H[Weekly K+ monitoring]:::action G --> H H --> I{K+ normalizes?}:::decision I -->|Yes| J[Continue outpatient follow-up]:::outcome I -->|No| K[Add cation exchanger or diuretic]:::action ``` ## Why Discontinuing Losartan Is Correct ### Mechanism of Hyperkalemia in This Patient - **Losartan (ARB):** Blocks angiotensin II → reduces aldosterone secretion → decreased renal K⁺ excretion. - **CKD stage 3b:** Reduced GFR (35) limits K⁺ filtration; kidneys are already compromised. - **Combined effect:** ARB + CKD = high risk of hyperkalemia. **High-Yield:** ARBs, ACE inhibitors, and K⁺-sparing diuretics are the **most common iatrogenic causes** of hyperkalemia in CKD. ### Alternative Antihypertensive - **Amlodipine (calcium channel blocker):** Does NOT affect K⁺ homeostasis; safe in CKD. - **Hydralazine + nitrate:** Alternative if CCB contraindicated. - **Avoid:** Further ACE-I, ARB, K⁺-sparing diuretics, NSAIDs. ### Dietary Modification - **Low-potassium diet:** Restrict K⁺ to <2000 mg/day (avoid bananas, oranges, tomatoes, potatoes, nuts). - **Gradual reduction:** Expected K⁺ drop of 0.5–1.0 mEq/L over 1–2 weeks. ### Monitoring - **Weekly K⁺ checks** until stable, then monthly. - **Target:** K⁺ <5.5 mEq/L. **Clinical Pearl:** In **asymptomatic or mildly symptomatic hyperkalemia without ECG changes**, the goal is to **identify and remove the cause** (usually a drug) and allow gradual K⁺ normalization. Acute interventions (calcium, insulin, dialysis) are **not indicated** and may overcorrect, causing hypokalemia. ## Why Acute Interventions Are Inappropriate Here **Warning:** Insulin, calcium, and dialysis are reserved for **severe symptomatic hyperkalemia with ECG changes**. Using them in this patient would be: - **Unnecessary:** No cardiac risk. - **Harmful:** Risk of overcorrection → hypokalemia → cardiac arrhythmias, muscle weakness. - **Inefficient:** Acute shifts do not address the underlying cause (losartan). [cite:Harrison 21e Ch 280; KD Tripathi 8e Ch 12]